Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.An experimental drug to lower cholesterol has shown promise, according to a study presented Wednesday at a meeting of the American Heart Association.
The drug developed by pharmaceutical giant Merck is known as anacetrapib and showed significant decreases in "bad" cholesterol and likewise boosted "good" cholesterol levels.
The study, which has also been published in the New England Journal of Medicine, showed drops in LDL levels of cholesterol of 40 percent, while good cholesterol, or HDL levels, were lifted by 138 percent.
"These results are promising and serve as the basis for our decision to further develop anacetrapib," said Michael Mendelsohn, a lead doctor at Merck Research Laboratories.
"We look forward to continuing to study anacetrapib in a large cardiovascular clinical outcomes trial."
The company next aims to launch a 30,000 patient study over several years to determine the drug's effects over a wider sample of the population, and will monitor if the drug can reduce the risk of heart attack and stroke.
The 76-week study just completed showed a two-percent death rate due to cardiac arrest or stroke in patients treated with the drug, compared to 2.6 percent who took a placebo, Merck said.
The trial did not analyze the drug's effects on blood pressure, a problem that forces US lab Pfizer to abandon its bid in 2006 to develop a similar drug.
js/ksh/rl
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments